Browsing Tag
Chris Boshoff
6 posts
Pfizer’s immunotherapy ELREXFIO approved in EU for multiple myeloma
Pfizer Inc. has announced a significant development in the treatment of multiple myeloma, a type of cancer that…
Pfizer to acquire cancer-focused drugmaker Seagen in $43bn deal to expand oncology leadership
Pfizer is set to acquire Seagen for $43 billion in cash to boost its oncology drug pipeline and antibody-drug conjugate capabilities. Learn how the deal reshapes cancer therapeutics.
Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn
US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company,…
Pfizer’s IBRANCE fails to meet primary endpoint in PENELOPE-B breast cancer trial
The latest results from Pfizer’s Phase 3 PENELOPE-B clinical trial have cast a shadow over the potential of…
Ibrance FDA approval : Pfizer breast cancer drug approved for metastatic breast cancer in men
New Ibrance FDA approval : The US Food and Drug Administration (FDA) has extended the approval of Pfizer…
Vyriad and Merck launch Phase 1 trial for innovative immuno-oncology drug combination
Vyriad, a US-based biotech company, has partnered with Germany’s Merck to initiate a Phase 1 clinical trial targeting…